Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an American Association for the Study of Liver Diseases–U.S. Food and Drug Administration Joint Workshop
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease (CLD) in North America. It is a growing contributor to the burden of CDL requiring liver transplantation. Cirrhosis is also associated with an increased risk of hepatocellular cancer, which may occur even in t...
Saved in:
| Published in | Hepatology (Baltimore, Md.) Vol. 61; no. 4; pp. 1392 - 1405 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Wolters Kluwer Health, Inc
01.04.2015
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0270-9139 1527-3350 1527-3350 |
| DOI | 10.1002/hep.27678 |
Cover
| Abstract | Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease (CLD) in North America. It is a growing contributor to the burden of CDL requiring liver transplantation. Cirrhosis is also associated with an increased risk of hepatocellular cancer, which may occur even in the absence of cirrhosis in subjects with nonalcoholic steatohepatitis (NASH), the histological form of NAFLD associated with increased liver‐related mortality. The diagnosis of NASH currently requires a liver biopsy. There are also no U.S. Food and Drug Administration (FDA)‐approved therapies for NASH. Therefore, there is a need to develop better diagnostic and therapeutic strategies for patients with NASH, targeting both those with early‐stage disease as well as those with advanced liver fibrosis. There are unique challenges in the design of studies for these target populations. The long relatively asymptomatic time interval in the progression of NAFLD and NASH to cirrhosis and ultimately liver failure, along with gaps in knowledge regarding disease modifiers, combine to present significant challenges in trial design. Therefore, there is an urgent need to develop methods to identify the populations at particular risk of disease progression and validate endpoints that reflect meaningful changes in health status in this population. This article summarizes the discussion at a joint workshop held September 5 and 6, 2013 in Silver Spring, Maryland, sponsored by the FDA and the American Association for the Study of Liver Diseases to develop guidance on diagnostic and therapeutic modalities for NASH. (Hepatology 2015;61:1392–1405) |
|---|---|
| AbstractList | Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease (CLD) in North America. It is a growing contributor to the burden of CDL requiring liver transplantation. Cirrhosis is also associated with an increased risk of hepatocellular cancer, which may occur even in the absence of cirrhosis in subjects with nonalcoholic steatohepatitis (NASH), the histological form of NAFLD associated with increased liver-related mortality. The diagnosis of NASH currently requires a liver biopsy. There are also no U.S. Food and Drug Administration (FDA)-approved therapies for NASH. Therefore, there is a need to develop better diagnostic and therapeutic strategies for patients with NASH, targeting both those with early-stage disease as well as those with advanced liver fibrosis. There are unique challenges in the design of studies for these target populations. The long relatively asymptomatic time interval in the progression of NAFLD and NASH to cirrhosis and ultimately liver failure, along with gaps in knowledge regarding disease modifiers, combine to present significant challenges in trial design. Therefore, there is an urgent need to develop methods to identify the populations at particular risk of disease progression and validate endpoints that reflect meaningful changes in health status in this population. This article summarizes the discussion at a joint workshop held September 5 and 6, 2013 in Silver Spring, Maryland, sponsored by the FDA and the American Association for the Study of Liver Diseases to develop guidance on diagnostic and therapeutic modalities for NASH.Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease (CLD) in North America. It is a growing contributor to the burden of CDL requiring liver transplantation. Cirrhosis is also associated with an increased risk of hepatocellular cancer, which may occur even in the absence of cirrhosis in subjects with nonalcoholic steatohepatitis (NASH), the histological form of NAFLD associated with increased liver-related mortality. The diagnosis of NASH currently requires a liver biopsy. There are also no U.S. Food and Drug Administration (FDA)-approved therapies for NASH. Therefore, there is a need to develop better diagnostic and therapeutic strategies for patients with NASH, targeting both those with early-stage disease as well as those with advanced liver fibrosis. There are unique challenges in the design of studies for these target populations. The long relatively asymptomatic time interval in the progression of NAFLD and NASH to cirrhosis and ultimately liver failure, along with gaps in knowledge regarding disease modifiers, combine to present significant challenges in trial design. Therefore, there is an urgent need to develop methods to identify the populations at particular risk of disease progression and validate endpoints that reflect meaningful changes in health status in this population. This article summarizes the discussion at a joint workshop held September 5 and 6, 2013 in Silver Spring, Maryland, sponsored by the FDA and the American Association for the Study of Liver Diseases to develop guidance on diagnostic and therapeutic modalities for NASH. Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease (CLD) in North America. It is a growing contributor to the burden of CDL requiring liver transplantation. Cirrhosis is also associated with an increased risk of hepatocellular cancer, which may occur even in the absence of cirrhosis in subjects with nonalcoholic steatohepatitis (NASH), the histological form of NAFLD associated with increased liver-related mortality. The diagnosis of NASH currently requires a liver biopsy. There are also no U.S. Food and Drug Administration (FDA)-approved therapies for NASH. Therefore, there is a need to develop better diagnostic and therapeutic strategies for patients with NASH, targeting both those with early-stage disease as well as those with advanced liver fibrosis. There are unique challenges in the design of studies for these target populations. The long relatively asymptomatic time interval in the progression of NAFLD and NASH to cirrhosis and ultimately liver failure, along with gaps in knowledge regarding disease modifiers, combine to present significant challenges in trial design. Therefore, there is an urgent need to develop methods to identify the populations at particular risk of disease progression and validate endpoints that reflect meaningful changes in health status in this population. This article summarizes the discussion at a joint workshop held September 5 and 6, 2013 in Silver Spring, Maryland, sponsored by the FDA and the American Association for the Study of Liver Diseases to develop guidance on diagnostic and therapeutic modalities for NASH. (Hepatology 2015;61:1392-1405) Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease (CLD) in North America. It is a growing contributor to the burden of CDL requiring liver transplantation. Cirrhosis is also associated with an increased risk of hepatocellular cancer, which may occur even in the absence of cirrhosis in subjects with nonalcoholic steatohepatitis (NASH), the histological form of NAFLD associated with increased liver-related mortality. The diagnosis of NASH currently requires a liver biopsy. There are also no U.S. Food and Drug Administration (FDA)-approved therapies for NASH. Therefore, there is a need to develop better diagnostic and therapeutic strategies for patients with NASH, targeting both those with early-stage disease as well as those with advanced liver fibrosis. There are unique challenges in the design of studies for these target populations. The long relatively asymptomatic time interval in the progression of NAFLD and NASH to cirrhosis and ultimately liver failure, along with gaps in knowledge regarding disease modifiers, combine to present significant challenges in trial design. Therefore, there is an urgent need to develop methods to identify the populations at particular risk of disease progression and validate endpoints that reflect meaningful changes in health status in this population. This article summarizes the discussion at a joint workshop held September 5 and 6, 2013 in Silver Spring, Maryland, sponsored by the FDA and the American Association for the Study of Liver Diseases to develop guidance on diagnostic and therapeutic modalities for NASH. Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease (CLD) in North America. It is a growing contributor to the burden of CDL requiring liver transplantation. Cirrhosis is also associated with an increased risk of hepatocellular cancer, which may occur even in the absence of cirrhosis in subjects with nonalcoholic steatohepatitis (NASH), the histological form of NAFLD associated with increased liver‐related mortality. The diagnosis of NASH currently requires a liver biopsy. There are also no U.S. Food and Drug Administration (FDA)‐approved therapies for NASH. Therefore, there is a need to develop better diagnostic and therapeutic strategies for patients with NASH, targeting both those with early‐stage disease as well as those with advanced liver fibrosis. There are unique challenges in the design of studies for these target populations. The long relatively asymptomatic time interval in the progression of NAFLD and NASH to cirrhosis and ultimately liver failure, along with gaps in knowledge regarding disease modifiers, combine to present significant challenges in trial design. Therefore, there is an urgent need to develop methods to identify the populations at particular risk of disease progression and validate endpoints that reflect meaningful changes in health status in this population. This article summarizes the discussion at a joint workshop held September 5 and 6, 2013 in Silver Spring, Maryland, sponsored by the FDA and the American Association for the Study of Liver Diseases to develop guidance on diagnostic and therapeutic modalities for NASH. (H epatology 2015;61:1392–1405) |
| Author | McCullough, Arthur J. Friedman, Scott L. Dimick‐Santos, Lara Sanyal, Arun J. |
| Author_xml | – sequence: 1 givenname: Arun J. surname: Sanyal fullname: Sanyal, Arun J. organization: Virginia Commonwealth University School of Medicine – sequence: 2 givenname: Scott L. surname: Friedman fullname: Friedman, Scott L. organization: Icahn School of Medicine at Mount Sinai – sequence: 3 givenname: Arthur J. surname: McCullough fullname: McCullough, Arthur J. organization: Cleveland Clinic Lerner College of Medicine – sequence: 4 givenname: Lara surname: Dimick‐Santos fullname: Dimick‐Santos, Lara organization: U.S. Food and Drug Administration |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25557690$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNks2O0zAQgCO0iP2BAy-ALHGBQ7u2E8cOt6q7ZUGVQFpWHCPXmbTeTTzBThb1xjvwhtx5B9y0e1mBxMmW55vPo5k5TY4cOkiSl4xOGaX8fAPdlMtcqifJCRNcTtJU0KPkhHJJJwVLi-PkNIRbSmmRcfUsOeZCCJkX9CT5Pd_opgG3hkC0qwh2Hfp-cLa38cU6UvlhPUZWFlvt78CTCu6hwa4F15MaPYnV6MbgBhtrSOhB9xgr0n10hHdkYV1l3Xqv92CwjYlVjKILpPbYxgCZteCt2V1CQGPH6OjuN0Cu-6HaEqzJ0t7H7y9sAB0g_Prx82Z6PSULxGqUX-xKnVWtdTb0fu_4iDZW-RX9Xdhg9zx5WusmwIvDeZbcLC6_zK8my0_vP8xny4kRiqtJHpsJikOd51rkXKSZWWnGhBSyUoYXPFVKsUzWNFtJxgopwXCRKZFKo7MiT8-SN3tv5_HbAKEvWxsMNI12gEMoWS7TVEWS_wcaWcG42FlfP0JvcfCx9yOVp1QIlUbq1YEaVi1UZedtnNu2fJh5BM73gPEYgoe6NLYfuxWbZpuS0XK3VWWcYTluVcx4-yjjQfo39mD_bhvY_hssry4_7zP-AFuD38E |
| CODEN | HPTLD9 |
| CitedBy_id | crossref_primary_10_3390_nu16172940 crossref_primary_10_1186_s12986_017_0223_1 crossref_primary_10_1016_j_cgh_2023_04_011 crossref_primary_10_1016_j_jhep_2017_11_012 crossref_primary_10_1097_MCG_0000000000001142 crossref_primary_10_1158_1055_9965_EPI_21_0754 crossref_primary_10_1016_j_jhep_2024_06_008 crossref_primary_10_1016_j_jpeds_2018_05_024 crossref_primary_10_1177_2472630317717049 crossref_primary_10_1007_s43440_019_00020_1 crossref_primary_10_1016_S2468_1253_19_30383_8 crossref_primary_10_1016_j_jcmgh_2019_04_007 crossref_primary_10_1371_journal_pone_0275901 crossref_primary_10_1111_apt_17762 crossref_primary_10_1111_apt_14492 crossref_primary_10_1016_j_metabol_2016_01_013 crossref_primary_10_1002_cncr_34799 crossref_primary_10_1016_j_jhep_2018_08_008 crossref_primary_10_1016_j_jhepr_2021_100322 crossref_primary_10_1007_s40618_017_0799_3 crossref_primary_10_17116_profmed201831262 crossref_primary_10_1002_hep_28031 crossref_primary_10_1111_apt_13951 crossref_primary_10_1016_j_lfs_2021_119220 crossref_primary_10_1111_apt_13833 crossref_primary_10_1053_j_gastro_2016_02_044 crossref_primary_10_3350_cmh_2022_0431 crossref_primary_10_1002_hep4_1079 crossref_primary_10_1111_dom_14322 crossref_primary_10_3390_biomedicines10030550 crossref_primary_10_1038_ctg_2016_28 crossref_primary_10_1056_NEJMra1610570 crossref_primary_10_1186_s12944_018_0720_x crossref_primary_10_26442_00403660_2024_02_202582 crossref_primary_10_1016_S0140_6736_16_30672_9 crossref_primary_10_1007_s40265_015_0437_3 crossref_primary_10_1016_j_lpm_2019_09_015 crossref_primary_10_1371_journal_pone_0153497 crossref_primary_10_1111_liv_14368 crossref_primary_10_1111_apt_15249 crossref_primary_10_3892_wasj_2024_245 crossref_primary_10_1172_JCI122132 crossref_primary_10_3390_diagnostics10100784 crossref_primary_10_1007_s12072_019_09935_6 crossref_primary_10_1016_j_jhep_2016_04_005 crossref_primary_10_1016_j_jhep_2019_03_004 crossref_primary_10_3748_wjg_v23_i23_4181 crossref_primary_10_4103_jcsr_jcsr_174_22 crossref_primary_10_1053_j_gastro_2017_07_024 crossref_primary_10_1016_j_jhep_2015_11_004 crossref_primary_10_1080_17474124_2017_1374851 crossref_primary_10_1016_j_diabet_2021_101281 crossref_primary_10_1186_s12944_016_0321_5 crossref_primary_10_1097_MOG_0000000000000356 crossref_primary_10_1136_gutjnl_2016_312431 crossref_primary_10_1186_s12916_018_1136_1 crossref_primary_10_1016_j_bbrc_2022_12_039 crossref_primary_10_1111_jgh_13625 crossref_primary_10_3390_children5060064 crossref_primary_10_1002_hep_27999 crossref_primary_10_1016_j_cmet_2022_10_007 crossref_primary_10_1136_bmjopen_2020_037961 crossref_primary_10_1007_s11695_017_2606_9 crossref_primary_10_1016_j_lfs_2017_03_012 crossref_primary_10_1096_fj_202002671RR crossref_primary_10_1111_liv_14749 crossref_primary_10_1016_j_biopha_2020_110138 crossref_primary_10_1016_j_freeradbiomed_2019_05_029 crossref_primary_10_1016_j_ejphar_2021_173976 crossref_primary_10_1093_toxsci_kfaa169 crossref_primary_10_3748_wjg_v26_i3_279 crossref_primary_10_1007_s10620_016_4128_z crossref_primary_10_1146_annurev_pharmtox_010617_052545 crossref_primary_10_1016_j_bcp_2022_115250 crossref_primary_10_1021_acsomega_0c02350 crossref_primary_10_1016_j_cgh_2017_02_031 crossref_primary_10_1002_hep_31108 crossref_primary_10_1016_j_tips_2019_05_002 crossref_primary_10_1152_ajpgi_00283_2016 crossref_primary_10_4254_wjh_v14_i1_119 crossref_primary_10_1016_j_molmet_2017_07_016 crossref_primary_10_1186_s41687_023_00589_5 crossref_primary_10_1038_nrgastro_2017_155 crossref_primary_10_3390_metabo14010040 crossref_primary_10_3390_antiox13070754 crossref_primary_10_22416_1382_4376_2022_32_4_104_140 crossref_primary_10_1021_acs_jmedchem_0c00640 crossref_primary_10_1016_j_jep_2020_113121 crossref_primary_10_1111_apt_15537 crossref_primary_10_1111_liv_13302 crossref_primary_10_18632_oncotarget_8641 crossref_primary_10_1002_hep_29724 crossref_primary_10_1016_j_jcmgh_2020_06_001 crossref_primary_10_4093_dmj_2016_40_1_1 crossref_primary_10_1016_j_heliyon_2024_e28468 crossref_primary_10_1016_j_ejps_2024_106808 crossref_primary_10_1016_j_cld_2023_01_010 crossref_primary_10_1186_s12944_024_02231_9 crossref_primary_10_1007_s00535_018_01542_w crossref_primary_10_3389_fphar_2022_893336 crossref_primary_10_3390_ijms24010158 crossref_primary_10_1126_scitranslmed_aav9701 crossref_primary_10_1016_j_jhepr_2020_100099 crossref_primary_10_1007_s00125_016_4094_1 crossref_primary_10_1371_journal_pone_0207479 crossref_primary_10_1053_j_gastro_2015_11_017 crossref_primary_10_1186_s12864_018_4575_3 crossref_primary_10_1016_j_jhep_2021_11_012 crossref_primary_10_1111_liv_14727 crossref_primary_10_1016_j_cgh_2015_07_029 crossref_primary_10_1016_S2468_1253_17_30365_5 crossref_primary_10_1186_s12916_017_0806_8 crossref_primary_10_1038_srep31421 crossref_primary_10_1002_ar_23954 crossref_primary_10_1016_j_ebiom_2015_06_008 crossref_primary_10_1124_dmd_121_000388 crossref_primary_10_22141_2224_0721_17_4_2021_237350 crossref_primary_10_1002_hep_29607 crossref_primary_10_1016_j_nut_2016_09_001 crossref_primary_10_1371_journal_pone_0283743 crossref_primary_10_3389_fcvm_2022_842980 crossref_primary_10_1080_03602532_2017_1293683 crossref_primary_10_3748_wjg_v24_i30_3361 crossref_primary_10_1016_j_cld_2021_01_002 crossref_primary_10_1016_j_jhepr_2020_100067 crossref_primary_10_1039_D1MO00274K crossref_primary_10_1016_j_ebiom_2023_104543 crossref_primary_10_1016_j_cgh_2017_12_023 crossref_primary_10_1016_j_cct_2021_106335 crossref_primary_10_1093_oncolo_oyac251 crossref_primary_10_1002_cpt_1978 crossref_primary_10_3389_fphar_2023_1149665 crossref_primary_10_1016_j_jhep_2018_05_036 crossref_primary_10_3390_ijms251910595 crossref_primary_10_1016_j_vascn_2019_106651 crossref_primary_10_3389_fcvm_2021_824481 crossref_primary_10_1016_j_yrtph_2019_104483 crossref_primary_10_1371_journal_pone_0221066 crossref_primary_10_1053_j_gastro_2015_09_015 crossref_primary_10_1155_2022_3538103 crossref_primary_10_1038_s41598_020_59485_3 crossref_primary_10_1021_acs_jafc_4c00152 crossref_primary_10_3390_nu11112586 crossref_primary_10_1016_j_cgh_2023_02_003 crossref_primary_10_3389_fgene_2022_971484 crossref_primary_10_1016_j_cld_2015_10_009 crossref_primary_10_1016_j_drudis_2017_06_007 crossref_primary_10_1016_j_jhep_2022_04_002 crossref_primary_10_1152_ajpgi_00158_2018 crossref_primary_10_3390_cells12010104 crossref_primary_10_1186_s12944_023_01867_3 crossref_primary_10_14218_JCTH_2017_00013 crossref_primary_10_1016_j_cct_2018_04_002 crossref_primary_10_1016_j_ebiom_2015_05_018 crossref_primary_10_1155_2021_9963534 crossref_primary_10_3390_chemosensors11040241 crossref_primary_10_1053_j_gastro_2016_03_008 crossref_primary_10_1080_13543784_2020_1668375 crossref_primary_10_1002_hep_28672 crossref_primary_10_1111_apt_15738 crossref_primary_10_1053_j_gastro_2016_04_038 crossref_primary_10_1055_s_0042_1749644 crossref_primary_10_1007_s12072_015_9695_0 crossref_primary_10_3748_wjg_v23_i47_8263 crossref_primary_10_1186_s13063_020_4201_y crossref_primary_10_2217_bmm_2017_0361 crossref_primary_10_1038_s41598_018_33949_z crossref_primary_10_1097_01_ELX_0000530862_04453_70 crossref_primary_10_2147_HMER_S265473 crossref_primary_10_1053_j_gastro_2016_03_004 crossref_primary_10_1186_s40779_023_00487_3 crossref_primary_10_1002_hep_30986 crossref_primary_10_1016_j_jhep_2015_02_041 crossref_primary_10_1016_j_rgmx_2018_11_007 crossref_primary_10_1055_s_0041_1732354 crossref_primary_10_1016_j_rgmxen_2019_02_003 crossref_primary_10_1038_s41591_018_0104_9 crossref_primary_10_1080_14656566_2018_1531126 crossref_primary_10_1007_s11938_015_0053_z crossref_primary_10_1016_j_jhep_2017_09_024 crossref_primary_10_3390_jpm11060499 crossref_primary_10_1016_j_omtm_2016_11_004 crossref_primary_10_1152_ajpgi_00041_2019 crossref_primary_10_1097_MD_0000000000022867 crossref_primary_10_1038_nrgastro_2018_10 crossref_primary_10_1016_j_jhep_2017_12_001 crossref_primary_10_1053_j_gastro_2016_03_014 crossref_primary_10_1002_hep_29090 crossref_primary_10_1002_hep_32033 crossref_primary_10_1097_MEG_0000000000001614 crossref_primary_10_1080_14728214_2021_1918099 crossref_primary_10_1016_j_bbadis_2015_05_015 crossref_primary_10_3390_pr9091516 crossref_primary_10_26693_jmbs04_01_149 crossref_primary_10_3390_jcm10050930 crossref_primary_10_1053_j_gastro_2016_01_038 crossref_primary_10_1038_nrgastro_2017_32 crossref_primary_10_1016_j_biopha_2021_112372 crossref_primary_10_1080_17460441_2020_1811674 crossref_primary_10_1097_MD_0000000000004529 crossref_primary_10_1002_hep_30765 crossref_primary_10_1007_s12072_017_9838_6 crossref_primary_10_1111_bph_14503 crossref_primary_10_3748_wjg_v24_i2_179 crossref_primary_10_1292_jvms_18_0119 crossref_primary_10_1016_j_jceh_2020_07_003 crossref_primary_10_2957_kanzo_65_305 crossref_primary_10_4155_bio_2018_0286 crossref_primary_10_3389_fnut_2025_1508106 crossref_primary_10_3390_life14010037 crossref_primary_10_1016_j_semcdb_2020_02_012 crossref_primary_10_1053_j_gastro_2017_06_016 crossref_primary_10_3389_fmed_2020_00395 crossref_primary_10_1007_s11901_023_00595_7 crossref_primary_10_1371_journal_pone_0198937 crossref_primary_10_1021_acs_jmedchem_3c01431 crossref_primary_10_1016_j_ijpharm_2024_124381 crossref_primary_10_1016_j_phymed_2022_154235 crossref_primary_10_1111_liv_12975 crossref_primary_10_3390_nu14020386 crossref_primary_10_1016_j_cct_2019_105922 crossref_primary_10_1016_j_jhep_2019_09_018 crossref_primary_10_3389_fendo_2021_615409 crossref_primary_10_1177_1756283X15621232 crossref_primary_10_1007_s10620_016_4062_0 crossref_primary_10_1053_j_gastro_2015_06_016 crossref_primary_10_1038_s41575_019_0144_8 crossref_primary_10_1016_S2468_1253_16_30011_5 crossref_primary_10_1016_j_jhep_2015_02_005 crossref_primary_10_1111_liv_13270 crossref_primary_10_1056_NEJMra1503519 crossref_primary_10_1016_j_clinre_2020_03_021 crossref_primary_10_3350_cmh_2018_0037 crossref_primary_10_1002_hep_28484 crossref_primary_10_2174_1874467215666211217120448 crossref_primary_10_1016_j_phymed_2023_154661 crossref_primary_10_1097_MEG_0000000000001393 crossref_primary_10_1007_s00125_016_3902_y crossref_primary_10_1111_liv_13480 crossref_primary_10_1111_1751_2980_12830 crossref_primary_10_1177_2472630317747198 crossref_primary_10_1002_jgh3_12315 crossref_primary_10_3390_molecules26113316 crossref_primary_10_1016_j_cct_2016_02_012 crossref_primary_10_1038_s41467_023_39404_6 crossref_primary_10_7759_cureus_25495 crossref_primary_10_1002_hep_30314 crossref_primary_10_1002_hep_30672 crossref_primary_10_1016_S2468_1253_17_30005_5 crossref_primary_10_1016_j_phymed_2024_155703 crossref_primary_10_1194_jlr_M093799 crossref_primary_10_1146_annurev_physiol_021115_105331 crossref_primary_10_1089_ten_tea_2019_0101 crossref_primary_10_1016_j_drudis_2018_09_020 crossref_primary_10_5497_wjp_v9_i1_1 crossref_primary_10_1111_apt_14621 crossref_primary_10_1016_j_cgh_2017_09_044 crossref_primary_10_1038_s41598_018_32722_6 crossref_primary_10_3748_wjg_v22_i36_8226 crossref_primary_10_1159_000443344 crossref_primary_10_1038_s41598_017_10930_w crossref_primary_10_3389_fendo_2021_777075 crossref_primary_10_1111_apt_15153 crossref_primary_10_1007_s11901_016_0305_y crossref_primary_10_1016_S1957_2557_17_30167_0 crossref_primary_10_1111_apt_17456 crossref_primary_10_2147_DMSO_S254555 crossref_primary_10_1053_j_gastro_2021_10_051 crossref_primary_10_26442_00403660_2022_02_201363 crossref_primary_10_3350_cmh_2020_0181 |
| Cites_doi | 10.1038/ajg.2011.157 10.1007/s11894-008-0011-1 10.1038/nrgastro.2013.171 10.1016/j.cgh.2008.11.005 10.1002/hep.20842 10.1038/ajg.2010.152 10.1093/carcin/bgq050 10.1053/j.gastro.2013.06.057 10.1016/j.transproceed.2004.03.095 10.1016/j.pcd.2010.02.004 10.1002/hep.20701 10.1185/03007995.2010.506375 10.1002/hep.23527 10.1002/hep.20871 10.1002/hep.20062 10.1053/j.gastro.2005.04.014 10.1016/j.jhep.2005.10.013 10.1016/j.jpeds.2009.06.014 10.1038/nrgastro.2013.183 10.1002/hep.1840070124 10.1002/hep.21103 10.1016/j.jhep.2004.09.012 10.1111/j.1572-0241.1999.01377.x 10.1002/hep.23784 10.1053/gast.2003.50016 10.1111/j.1365-2036.2010.04484.x 10.1111/jgh.12156 10.1016/S0025-6196(24)00530-5 10.1002/hep.21327 10.1038/ajg.2014.264 10.1002/hep.24268 10.3748/wjg.15.2097 10.1016/j.bmcl.2009.04.047 10.1053/jhep.2001.22172 10.1053/j.gastro.2012.04.001 10.1053/j.gastro.2008.08.050 10.1111/j.1572-0241.2001.03956.x 10.1097/01.mpg.0000239995.58388.56 10.1002/lt.20265 10.1111/j.1572-0241.2008.02034.x 10.1016/S0016-5085(99)70506-8 10.1002/hep.24491 10.1111/j.1365-2893.2010.01371.x 10.1097/MPG.0b013e318192d224 10.1007/s10620-013-2743-5 10.1002/hep.26156 10.1002/hep.1840110114 10.1111/j.1478-3231.2011.02753.x 10.1002/hep.22868 10.1016/j.jhep.2009.03.025 10.1038/nrgastro.2013.41 10.1053/jhep.2003.50229 10.1097/01.psy.0000221276.17823.df 10.1111/j.1572-0241.2002.05922.x 10.1016/j.ab.2009.11.008 10.1055/s-2008-1040325 10.1053/j.gastro.2007.05.024 10.1038/nrgastro.2010.21 10.1002/hep.20466 10.1007/s11894-012-0301-5 10.2174/092986710790112666 10.1111/j.1478-3231.2012.02830.x 10.1053/j.gastro.2005.03.084 10.1111/j.1365-2036.2007.03426.x 10.1053/gast.2001.21193 10.1038/ajg.2010.18 10.1016/j.jhep.2009.01.014 10.1056/NEJMoa0907929 10.1053/j.gastro.2007.10.024 10.1016/S0016-5085(13)63534-9 10.1111/j.1365-2036.2009.04181.x |
| ContentType | Journal Article |
| Copyright | 2015 by the American Association for the Study of Liver Diseases 2015 by the American Association for the Study of Liver Diseases. |
| Copyright_xml | – notice: 2015 by the American Association for the Study of Liver Diseases – notice: 2015 by the American Association for the Study of Liver Diseases. |
| CorporateAuthor | United States Food and Drug Administration American Association for the Study of Liver Diseases |
| CorporateAuthor_xml | – name: American Association for the Study of Liver Diseases – name: United States Food and Drug Administration |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 7TM 7TO 7U9 H94 K9. 7X8 |
| DOI | 10.1002/hep.27678 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Virology and AIDS Abstracts Oncogenes and Growth Factors Abstracts Nucleic Acids Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic AIDS and Cancer Research Abstracts MEDLINE CrossRef AIDS and Cancer Research Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1527-3350 |
| EndPage | 1405 |
| ExternalDocumentID | 3634352051 25557690 10_1002_hep_27678 HEP27678 |
| Genre | article Research Support, U.S. Gov't, Non-P.H.S Research Support, Non-U.S. Gov't Journal Article Practice Guideline |
| GrantInformation_xml | – fundername: NIDDK NIH HHS grantid: R01 DK081410 |
| GroupedDBID | --- --K .3N .55 .GA .GJ .Y3 05W 0R~ 10A 186 1B1 1CY 1L6 1OB 1OC 1ZS 1~5 24P 31~ 33P 3O- 3SF 3WU 4.4 4G. 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5RE 5VS 7-5 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAEDT AAESR AAEVG AAHHS AALRI AANHP AAONW AAQFI AAQQT AAQXK AASGY AAXRX AAXUO AAZKR ABCQN ABCUV ABEML ABIJN ABLJU ABMAC ABOCM ABPVW ABWVN ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACLDA ACMXC ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADEOM ADIZJ ADKYN ADMGS ADMUD ADNMO ADOZA ADXAS ADZMN ADZOD AECAP AEEZP AEIMD AENEX AEQDE AEUQT AFBPY AFFNX AFGKR AFPWT AFUWQ AFZJQ AHMBA AIACR AIURR AIWBW AJAOE AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BAWUL BDRZF BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DU5 E3Z EBS EJD F00 F01 F04 F5P FD8 FDB FEDTE FGOYB FUBAC G-S G.N GNP GODZA H.X HBH HF~ HHY HHZ HVGLF HZ~ IHE IX1 J0M J5H JPC KBYEO KQQ LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M41 M65 MJL MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N4W N9A NF~ NNB NQ- O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K R2- RGB RIG RIWAO RJQFR ROL RPZ RWI RX1 RYL SEW SSZ SUPJJ TEORI UB1 V2E V9Y W2D W8V W99 WBKPD WH7 WHWMO WIB WIH WIJ WIK WIN WJL WOHZO WQJ WRC WUP WVDHM WXI X7M XG1 XV2 ZGI ZXP ZZTAW ~IA ~WT AAMMB AAYXX ABJNI ACZKN ADSXY AEFGJ AFNMH AGQPQ AGXDD AHQVU AIDQK AIDYY CITATION MEWTI WXSBR ACIJW CGR CUY CVF ECM EIF NPM 7T5 7TM 7TO 7U9 H94 K9. 7X8 |
| ID | FETCH-LOGICAL-c5828-6276e82ef66a562534cba115757d8c2923888147f04b711977ec2548537ca4963 |
| IEDL.DBID | DR2 |
| ISSN | 0270-9139 1527-3350 |
| IngestDate | Tue Aug 05 11:16:16 EDT 2025 Fri Sep 05 06:01:25 EDT 2025 Wed Aug 13 10:39:15 EDT 2025 Thu Apr 03 06:55:05 EDT 2025 Thu Apr 24 22:56:25 EDT 2025 Wed Sep 10 04:55:59 EDT 2025 Wed Jan 22 16:34:28 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Language | English |
| License | 2015 by the American Association for the Study of Liver Diseases. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5828-6276e82ef66a562534cba115757d8c2923888147f04b711977ec2548537ca4963 |
| Notes | Potential conflict of interest: Dr. Sanyal has stock options in Genfit. He has served as a consultant to AbbVie, Astra Zeneca, Nitto Denko, Nimbus, Salix, Tobira, Takeda, Fibrogen, Immuron, Exhalenz and Genfit. He has been an unpaid consultant to Intercept and Echosens. His institution has received grant support from Gilead, Salix, Tobira and Novartis. None of these are related to the current study. Dr. Friedman consults, owns stock in, and received grants from Galectin and Tobira; consults and owns stock in Intercept, Conatus, Exalenz, Genfit, and Kinemed; consults for AbbVie, AstraZeneca, Boehringer Ingelheim, Bristol‐Myers Squibb, DeuteRx, Fibrogen, Genentech/Roche, Gilead, Intermune, Nimbus, Nitto, Novartis, Pfizer, Pharmastrat, RuiYi, Sandhill, Sanofi Aventis, Synageva, and Vaccinex; and owns stock in Angion. This work was supported by the U.S. Food and Drug Administration by the American Association for the Study of Liver Diseases. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Instructional Material/Guideline-3 content type line 23 |
| OpenAccessLink | http://doi.org/10.1002/hep.27678 |
| PMID | 25557690 |
| PQID | 1666305583 |
| PQPubID | 996352 |
| PageCount | 14 |
| ParticipantIDs | proquest_miscellaneous_1673384962 proquest_miscellaneous_1667351256 proquest_journals_1666305583 pubmed_primary_25557690 crossref_citationtrail_10_1002_hep_27678 crossref_primary_10_1002_hep_27678 wiley_primary_10_1002_hep_27678_HEP27678 |
| PublicationCentury | 2000 |
| PublicationDate | April 2015 |
| PublicationDateYYYYMMDD | 2015-04-01 |
| PublicationDate_xml | – month: 04 year: 2015 text: April 2015 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Hoboken |
| PublicationTitle | Hepatology (Baltimore, Md.) |
| PublicationTitleAlternate | Hepatology |
| PublicationYear | 2015 |
| Publisher | Wolters Kluwer Health, Inc |
| Publisher_xml | – name: Wolters Kluwer Health, Inc |
| References | 1990; 11 2013; 28 2002; 97 2010; 105 2010; 17 1983; 7 1987; 7 2011; 53 2009; 155 2011; 54 2008; 103 2012; 56 2011; 18 2009; 49 2009; 48 2013; 15 2013; 58 2010; 26 2009; 51 2013; 10 2006; 68 2009; 50 2013; 57 2004; 39 2004; 36 2007; 133 2010; 398 2008; 28 1999; 94 2009; 19 2003; 124 2010; 4 2010; 7 2001; 96 2009; 15 2007; 26 2010; 32 2012; 142 2010; 31 2004; 40 2001; 120 2013; 145 2005; 41 2013; 144 2003; 37 2005; 42 2010; 362 2008; 10 2012; 32 2004; 10 2014; 109 2011; 106 2006; 43 2006; 44 1980; 55 2005; 128 2005; 129 1964 2009; 7 2008; 135 2008; 134 2001; 33 1999; 116 2010; 52 2010; 51 (hep27678-bib-0001-20241017) 2013; 10 (hep27678-bib-0047-20241017) 2001; 33 (hep27678-bib-0060-20241017) 2012; 32 (hep27678-bib-0027-20241017) 2011; 106 (hep27678-bib-0062-20241017) 2009; 19 (hep27678-bib-0069-20241017) 2013; 145 (hep27678-bib-0073-20241017) 2009; 48 (hep27678-bib-0072-20241017) 2009; 155 (hep27678-bib-0009-20241017) 2012; 142 (hep27678-bib-0023-20241017) 2009; 49 (hep27678-bib-0032-20241017) 2008; 134 (hep27678-bib-0016-20241017) 2005; 41 (hep27678-bib-0022-20241017) 2010; 31 (hep27678-bib-0038-20241017) 2012; 56 (hep27678-bib-0014-20241017) 2005; 42 (hep27678-bib-0050-20241017) 2013; 28 (hep27678-bib-0008-20241017) 1980; 55 (hep27678-bib-0028-20241017) 1987; 7 (hep27678-bib-0024-20241017) 2007; 26 (hep27678-bib-0020-20241017) 2013; 10 (hep27678-bib-0025-20241017) 2001; 96 (hep27678-bib-0042-20241017) 2014; 109 (hep27678-bib-0006-20241017) 2005; 129 (hep27678-bib-0003-20241017) 2010; 7 (hep27678-bib-0017-20241017) 1999; 94 (hep27678-bib-0029-20241017) 2006; 44 (hep27678-bib-0026-20241017) 2006; 68 (hep27678-bib-0070-20241017) 2013; 57 (hep27678-bib-0071-20241017) 2010; 105 (hep27678-bib-0031-20241017) 2007; 133 (hep27678-bib-0041-20241017) 2013; 15 (hep27678-bib-0049-20241017) 2004; 36 (hep27678-bib-0075-20241017) 2012; 32 (hep27678-bib-0019-20241017) 2005; 42 (hep27678-bib-0037-20241017) 1990; 11 (hep27678-bib-0043-20241017) 2013; 10 (hep27678-bib-0048-20241017) 2003; 124 (hep27678-bib-0052-20241017) 2010; 398 (hep27678-bib-0021-20241017) 2002; 97 (hep27678-bib-0040-20241017) 2001; 120 (hep27678-bib-0054-20241017) 2010; 17 (hep27678-bib-0044-20241017) 2011; 18 (hep27678-bib-0059-20241017) 1983; 7 (hep27678-bib-0015-20241017) 2006; 44 (hep27678-bib-0005-20241017) 2006; 43 (hep27678-bib-0066-20241017) 2011; 53 (hep27678-bib-0011-20241017) 2008; 10 (hep27678-bib-0013-20241017) 2003; 37 (hep27678-bib-0056-20241017) 2004; 10 (hep27678-bib-0035-20241017) 1999; 116 (hep27678-bib-0057-20241017) 2004; 39 (hep27678-bib-0012-20241017) 2008; 135 (hep27678-bib-0034-20241017) 2010; 26 (hep27678-bib-0030-20241017) 2006; 43 (hep27678-bib-0039-20241017) 2010; 362 (hep27678-bib-0053-20241017) 2009; 51 (hep27678-bib-0061-20241017) 2009; 15 (hep27678-bib-0010-20241017) 2010; 52 (hep27678-bib-0074-20241017) 2008; 103 (hep27678-bib-0033-20241017) 2011; 54 (hep27678-bib-0076-20241017) 2010; 105 (hep27678-bib-0007-20241017) 2009; 7 (hep27678-bib-0068-20241017) 2013; 58 (hep27678-bib-0004-20241017) 2004; 40 (hep27678-bib-0065-20241017) 2013; 144 (hep27678-bib-0018-20241017) 2013; 58 (hep27678-bib-0055-20241017) 2005; 42 (hep27678-bib-0002-20241017) 2010; 4 (hep27678-bib-0067-20241017) 2005; 128 (hep27678-bib-0036-20241017) 2010; 51 (hep27678-bib-0046-20241017) 2008; 28 (hep27678-bib-0051-20241017) 2010; 31 (hep27678-bib-0064-20241017) 2013; 58 (hep27678-bib-0063-20241017) 2009; 50 (hep27678-bib-0058-20241017) 2010; 32 20372110 - Am J Gastroenterol. 2010 Sep;105(9):2093-102 11208726 - Gastroenterology. 2001 Jan;120(1):170-8 17006923 - Hepatology. 2006 Oct;44(4):865-73 21050237 - Aliment Pharmacol Ther. 2010 Dec;32(11-12):1351-6 23175136 - Hepatology. 2013 Apr;57(4):1357-65 23250701 - Curr Gastroenterol Rep. 2013 Jan;15(1):301 17767465 - Aliment Pharmacol Ther. 2007 Sep 15;26(6):815-20 16012941 - Gastroenterology. 2005 Jul;129(1):113-21 21726509 - Gastroenterology. 2011 Oct;141(4):1249-53 23860502 - Gastroenterology. 2013 Oct;145(4):782-9.e4 20195271 - Nat Rev Gastroenterol Hepatol. 2010 Apr;7(4):195-203 10484010 - Am J Gastroenterol. 1999 Sep;94(9):2467-74 20648476 - Hepatology. 2010 Sep;52(3):913-24 15915461 - Hepatology. 2005 Jun;41(6):1313-21 20666689 - Curr Med Res Opin. 2010 Sep;26(9):2183-91 10220741 - Liver. 1999 Apr;19(2):115-21 22989165 - J Gastroenterol Hepatol. 2013 Jan;28(1):142-7 18417045 - Curr Gastroenterol Rep. 2008 Feb;10(1):67-72 24042449 - Nat Rev Gastroenterol Hepatol. 2013 Nov;10(11):686-90 10464138 - Gastroenterology. 1999 Sep;117(3):626-31 12774006 - Hepatology. 2003 Jun;37(6):1286-92 11172350 - Hepatology. 2001 Feb;33(2):464-70 23954643 - Clin Gastroenterol Hepatol. 2013 Dec;11(12):1573-84.e1-2; quiz e88-9 23507799 - Nat Rev Gastroenterol Hepatol. 2013 Jun;10(6):330-44 12512033 - Gastroenterology. 2003 Jan;124(1):91-6 15629518 - J Hepatol. 2005 Jan;42(1):132-8 6353113 - Lab Res Methods Biol Med. 1983;7:567-85 19434741 - Hepatology. 2009 Jun;49(6):1904-12 19863497 - Aliment Pharmacol Ther. 2010 Feb 1;31(3):396-406 16502396 - Hepatology. 2006 Apr;43(4):682-9 2227807 - Hepatology. 1990 Nov;12(5):1106-10 24247899 - Transplantation. 2013 Nov 27;96(10):860-2 21556040 - Am J Gastroenterol. 2011 Sep;106(9):1646-53 19412009 - J Pediatr Gastroenterol Nutr. 2009 May;48(5):597-603 21360720 - Hepatology. 2011 Jun;53(6):1874-82 16175621 - Hepatology. 2005 Oct;42(4):793-801 21155882 - J Gastroenterol Hepatol. 2011 Mar;26(3):510-6 20844956 - Dig Dis Sci. 2011 Apr;56(4):977-87 22299674 - Liver Int. 2012 Jul;32(6):945-50 20427778 - N Engl J Med. 2010 May 6;362(18):1675-85 20101752 - Hepatology. 2010 Feb;51(2):585-94 2295475 - Hepatology. 1990 Jan;11(1):74-80 19049831 - Clin Gastroenterol Hepatol. 2009 Feb;7(2):234-8 19772998 - J Pediatr. 2009 Oct;155(4):469-74 22656328 - Gastroenterology. 2012 Jun;142(7):1592-609 12648985 - Lancet. 2003 Mar 15;361(9361):952-4 18684196 - Am J Gastroenterol. 2008 Sep;103(9):2263-71 19773396 - J Clin Endocrinol Metab. 2009 Oct;94(10):3872-81 19013463 - Gastroenterology. 2008 Dec;135(6):1961-1971.e2 20460905 - Dig Dis. 2010;28(1):155-61 16116629 - Hepatology. 2005 Sep;42(3):641-9 15565570 - Hepatology. 2004 Dec;40(6):1387-95 15940625 - Gastroenterology. 2005 Jun;128(7):1898-906 20145609 - Am J Gastroenterol. 2010 Jul;105(7):1567-73 24375711 - Hepatology. 2014 Jun;59(6):2188-95 14767976 - Hepatology. 2004 Feb;39(2):280-2 18293281 - Semin Liver Dis. 2008 Feb;28(1):110-22 21688282 - Hepatology. 2011 Oct;54(4):1208-16 15382215 - Liver Transpl. 2004 Oct;10(10 Suppl 2):S69-73 15643990 - Am J Transplant. 2005 Feb;5(2):307-13 10733541 - Hepatology. 2000 Apr;31(4):864-71 10348825 - Gastroenterology. 1999 Jun;116(6):1413-9 18005961 - Gastroenterology. 2008 Jan;134(1):85-94 3804191 - Hepatology. 1987 Jan-Feb;7(1):122-8 2737595 - Hepatology. 1989 Jul;10(1):1-7 20209604 - Hepatology. 2010 Jun;51(6):1972-8 7382552 - Mayo Clin Proc. 1980 Jul;55(7):434-8 12190177 - Am J Gastroenterol. 2002 Aug;97(8):2058-62 17681169 - Gastroenterology. 2007 Aug;133(2):481-8 19293782 - Am J Gastroenterol. 2009 Apr;104(4):861-7 24607623 - J Hepatol. 2014 Jul;61(1):22-7 16868265 - Psychosom Med. 2006 Jul-Aug;68(4):563-9 20336705 - Hepatology. 2010 Jun;51(6):1979-87 2680867 - Hepatology. 1989 Nov;10(5):846-50 11467653 - Am J Gastroenterol. 2001 Jul;96(7):2199-205 16298014 - J Hepatol. 2006 Jan;44(1):217-31 20299294 - Prim Care Diabetes. 2010 Oct;4(3):129-37 17033514 - J Pediatr Gastroenterol Nutr. 2006 Oct;43(4):413-27 22679906 - Liver Int. 2012 Oct;32(9):1407-14 19303163 - J Hepatol. 2009 May;50(5):923-8 23775317 - Dig Dis Sci. 2013 Oct;58(10):3017-23 21431854 - Curr Diab Rep. 2011 Jun;11(3):167-72 |
| References_xml | – volume: 19 start-page: 2969 year: 2009 end-page: 2973 article-title: Substituted isoxazole analogs of farnesoid X receptor (FXR) agonist GW4064 publication-title: Bioorg Med Chem Lett – volume: 58 start-page: 495A year: 2013 article-title: Progression to bridging fibrosis in nonalcoholic fatty liver disease over 4 years in the NASH CRN publication-title: Hepatology – volume: 144 start-page: S951 year: 2013 article-title: Changes in serum cytokeratin 18 levels significantly predict changes in liver histology in adults with nonalcoholic steatohepatitis: results from the PIVENS Trial publication-title: Gastroenterology – volume: 105 start-page: 2093 year: 2010 end-page: 2102 article-title: Association between metabolic syndrome and liver histology among children with nonalcoholic Fatty liver disease publication-title: Am J Gastroenterol – volume: 41 start-page: 1313 year: 2005 end-page: 1321 article-title: Design and validation of a histological scoring system for nonalcoholic fatty liver disease publication-title: Hepatology – volume: 36 start-page: 920 year: 2004 end-page: 922 article-title: Liver transplant recipients mortality on the waiting list: long‐term comparison to Child-Pugh classification and MELD publication-title: Transplant Proc – volume: 96 start-page: 2199 year: 2001 end-page: 2205 article-title: Health‐related quality of life in chronic liver disease: the impact of type and severity of disease publication-title: Am J Gastroenterol – volume: 32 start-page: 945 year: 2012 end-page: 950 article-title: The Framingham risk score and heart disease in nonalcoholic fatty liver disease publication-title: Liver Int – volume: 43 start-page: 682 year: 2006 end-page: 689 article-title: Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C publication-title: Hepatology – volume: 142 start-page: 1592 year: 2012 end-page: 1609 article-title: The diagnosis and management of non‐alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology publication-title: Gastroenterology – volume: 97 start-page: 2058 year: 2002 end-page: 2062 article-title: Subacute liver failure in obese women publication-title: Am J Gastroenterol – volume: 7 start-page: 567 year: 1983 end-page: 585 article-title: Portal venous pressure measurement and its clinical significance publication-title: Lab Res Methods Biol Med – volume: 124 start-page: 91 year: 2003 end-page: 96 article-title: Model for end‐stage liver disease (MELD) and allocation of donor livers publication-title: Gastroenterology – volume: 44 start-page: 865 year: 2006 end-page: 873 article-title: Long‐term follow‐up of patients with NAFLD and elevated liver enzymes publication-title: Hepatology – volume: 51 start-page: 1972 year: 2010 end-page: 1978 article-title: The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis publication-title: Hepatology – volume: 54 start-page: 1208 year: 2011 end-page: 1216 article-title: The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study publication-title: Hepatology – volume: 17 start-page: 139 year: 2010 end-page: 159 article-title: Targetting farnesoid‐X‐receptor: from medicinal chemistry to disease treatment publication-title: Curr Med Chem – volume: 133 start-page: 481 year: 2007 end-page: 488 article-title: Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis publication-title: Gastroenterology – volume: 145 start-page: 782 year: 2013 end-page: 789 article-title: Simple noninvasive systems predict long‐term outcomes of patients with nonalcoholic fatty liver disease publication-title: Gastroenterology – volume: 68 start-page: 563 year: 2006 end-page: 569 article-title: Depression, anxiety, and nonalcoholic steatohepatitis publication-title: Psychosom Med – volume: 33 start-page: 464 year: 2001 end-page: 470 article-title: A model to predict survival in patients with end‐stage liver disease publication-title: Hepatology – volume: 155 start-page: 469 year: 2009 end-page: 474 article-title: Pediatric nonalcoholic fatty liver disease in 2009 publication-title: J Pediatr – volume: 10 start-page: 330 year: 2013 end-page: 344 article-title: Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis publication-title: Nat Rev Gastroenterol Hepatol – volume: 32 start-page: 1407 year: 2012 end-page: 1414 article-title: Prognostic indicators of survival in patients with compensated and decompensated cirrhosis publication-title: Liver Int – volume: 31 start-page: 396 year: 2010 end-page: 406 article-title: Symptoms and quality of life in obese children and adolescents with non‐alcoholic fatty liver disease publication-title: Aliment Pharmacol Ther – volume: 129 start-page: 113 year: 2005 end-page: 121 article-title: The natural history of nonalcoholic fatty liver disease: a population‐based cohort study publication-title: Gastroenterology – volume: 7 start-page: 122 year: 1987 end-page: 128 article-title: Compensated cirrhosis: natural history and prognostic factors publication-title: Hepatology – volume: 55 start-page: 434 year: 1980 end-page: 438 article-title: Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease publication-title: Mayo Clin Proc – volume: 52 start-page: 913 year: 2010 end-page: 924 article-title: Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease publication-title: Hepatology – volume: 4 start-page: 129 year: 2010 end-page: 137 article-title: Non‐alcoholic fatty liver disease (NAFLD): new challenge for general practitioners and important burden for health authorities? publication-title: Prim Care Diabetes – volume: 15 start-page: 301 year: 2013 article-title: Quality of life in cirrhosis publication-title: Curr Gastroenterol Rep – volume: 58 start-page: 3017 year: 2013 end-page: 3023 article-title: Predictors of all‐cause mortality and liver‐related mortality in patients with non‐alcoholic fatty liver disease (NAFLD) publication-title: Dig Dis Sci – volume: 116 start-page: 1413 year: 1999 end-page: 1419 article-title: Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity publication-title: Gastroenterology – volume: 43 start-page: 413 year: 2006 end-page: 427 article-title: Pediatric nonalcoholic fatty liver disease: a critical appraisal of current data and implications for future research publication-title: J Pediatr Gastroenterol Nutr – volume: 105 start-page: 1567 year: 2010 end-page: 1573 article-title: Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community‐based cohort study publication-title: Am J Gastroenterol – volume: 7 start-page: 234 year: 2009 end-page: 238 article-title: Long‐term follow‐up of patients with nonalcoholic fatty liver publication-title: Clin Gastroenterol Hepatol – volume: 362 start-page: 1675 year: 2010 end-page: 1685 article-title: Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis publication-title: N Engl J Med – volume: 106 start-page: 1646 year: 2011 end-page: 1653 article-title: The multi‐dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers publication-title: Am J Gastroenterol – volume: 51 start-page: 380 year: 2009 end-page: 388 article-title: Farnesoid X receptor agonist WAY‐362450 attenuates liver inflammation and fibrosis in murine model of non‐alcoholic steatohepatitis publication-title: J Hepatol – volume: 44 start-page: 217 year: 2006 end-page: 231 article-title: Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies publication-title: J Hepatol – volume: 57 start-page: 1357 year: 2013 end-page: 1365 article-title: Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States publication-title: Hepatology – volume: 26 start-page: 815 year: 2007 end-page: 820 article-title: Health‐related quality of life in patients with non‐alcoholic fatty liver disease publication-title: Aliment Pharmacol Ther – volume: 15 start-page: 2097 year: 2009 end-page: 2108 article-title: Bile‐acid‐activated farnesoid X receptor regulates hydrogen sulfide production and hepatic microcirculation publication-title: World J Gastroenterol – volume: 134 start-page: 85 year: 2008 end-page: 94 article-title: Impact of fatty liver disease on health care utilization and costs in a general population: a 5‐year observation publication-title: Gastroenterology – volume: 26 start-page: 2183 year: 2010 end-page: 2191 article-title: Population‐based risk factors and resource utilization for HCC: US perspective publication-title: Curr Med Res Opin – volume: 120 start-page: 170 year: 2001 end-page: 178 article-title: Factors associated with poor health‐related quality of life of patients with cirrhosis publication-title: Gastroenterology – volume: 103 start-page: 2263 year: 2008 end-page: 2271 article-title: Suspected nonalcoholic fatty liver disease and mortality risk in a population‐based cohort study publication-title: Am J Gastroenterol – volume: 10 start-page: 686 year: 2013 end-page: 690 article-title: The global NAFLD epidemic publication-title: Nat Rev Gastroenterol Hepatol – volume: 10 start-page: 67 year: 2008 end-page: 72 article-title: The obesity epidemic and nonalcoholic fatty liver disease in children publication-title: Curr Gastroenterol Rep – volume: 398 start-page: 185 year: 2010 end-page: 190 article-title: Identification of farnesoid X receptor modulators by a fluorescence polarization‐based interaction assay publication-title: Anal Biochem – volume: 10 start-page: S69 year: 2004 end-page: S73 article-title: When is a patient too well and when is a patient too sick for a liver transplant? publication-title: Liver Transpl – volume: 42 start-page: 641 year: 2005 end-page: 649 article-title: Histopathology of pediatric nonalcoholic fatty liver disease publication-title: Hepatology – volume: 48 start-page: 597 year: 2009 end-page: 603 article-title: Trends in nonalcoholic fatty liver disease‐related hospitalizations in US children, adolescents, and young adults publication-title: J Pediatr Gastroenterol Nutr – volume: 58 start-page: A114 year: 2013 article-title: Serum keratin fgragment 18 (CK18) levels significantly predict changes in liver histology in children and adolescents with nonalcoholic fatty liver disease: results from teh TONIC trial publication-title: Hepatology – volume: 135 start-page: 1961 year: 2008 end-page: 1971 article-title: Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis publication-title: Gastroenterology – volume: 10 start-page: 656 year: 2013 end-page: 665 article-title: NAFLD, NASH and liver cancer publication-title: Nat Rev Gastroenterol Hepatol – volume: 42 start-page: 132 year: 2005 end-page: 138 article-title: The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies publication-title: J Hepatol – start-page: 50 year: 1964 end-page: 58 – volume: 31 start-page: 1100 year: 2010 end-page: 1109 article-title: Sodium taurocholate inhibits intestinal adenoma formation in APCMin/+ mice, potentially through activation of the farnesoid X receptor publication-title: Carcinogenesis – volume: 7 start-page: 195 year: 2010 end-page: 203 article-title: Pathology of nonalcoholic fatty liver disease publication-title: Nat Rev Gastroenterol Hepatol – volume: 28 start-page: 110 year: 2008 end-page: 122 article-title: Assessment of prognosis of cirrhosis publication-title: Semin Liver Dis – volume: 94 start-page: 2467 year: 1999 end-page: 2474 article-title: Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions publication-title: Am J Gastroenterol – volume: 56 start-page: A1480 year: 2012 article-title: Histological predictors of improvement of NASH: results from NASH Clinical Research Network PIVENS trial publication-title: Hepatology – volume: 53 start-page: 1874 year: 2011 end-page: 1882 article-title: Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver‐related mortality publication-title: Hepatology – volume: 32 start-page: 1351 year: 2010 end-page: 1356 article-title: Comparison of balloon vs. straight catheter for the measurement of portal hypertension publication-title: Aliment Pharmacol Ther – volume: 128 start-page: 1898 year: 2005 end-page: 1906 article-title: Sampling variability of liver biopsy in nonalcoholic fatty liver disease publication-title: Gastroenterology – volume: 50 start-page: 923 year: 2009 end-page: 928 article-title: Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis publication-title: J Hepatol – volume: 39 start-page: 280 year: 2004 end-page: 282 article-title: The hepatic venous pressure gradient: anything worth doing should be done right publication-title: Hepatology – volume: 40 start-page: 1387 year: 2004 end-page: 1395 article-title: Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity publication-title: Hepatology – volume: 109 start-page: 1757 year: 2014 end-page: 1763 article-title: Covert hepatic encephalopathy is independently associated with poor survival and increased risk of hospitalization publication-title: Am J Gastroenterol – volume: 42 start-page: 793 year: 2005 end-page: 801 article-title: Influence of hepatic venous pressure gradient on the prediction of survival of patients with cirrhosis in the MELD era publication-title: Hepatology – volume: 37 start-page: 1286 year: 2003 end-page: 1292 article-title: Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values publication-title: Hepatology – volume: 11 start-page: 74 year: 1990 end-page: 80 article-title: The natural history of nonalcoholic steatohepatitis: a follow‐up study of forty‐two patients for up to 21 years publication-title: Hepatology – volume: 49 start-page: 1904 year: 2009 end-page: 1912 article-title: Quality of life in adults with nonalcoholic fatty liver disease: baseline data from the nonalcoholic steatohepatitis clinical research network publication-title: Hepatology – volume: 18 start-page: 685 year: 2011 end-page: 691 article-title: Use of transient elastography (FibroScan(R)) for the noninvasive assessment of portal hypertension in HIV/HCV‐coinfected patients publication-title: J Viral Hepat – volume: 28 start-page: 1209 year: 2013 end-page: 1216 article-title: Predictive value of refit MELD, refit MELD‐Na and pre-existing scoring system for 3 month mortality in Korean patients with cirrhosis publication-title: J Gastroenterol Hepatol – volume: 106 start-page: 1646 year: 2011 ident: hep27678-bib-0027-20241017 article-title: The multi‐dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers publication-title: Am J Gastroenterol doi: 10.1038/ajg.2011.157 – volume: 10 start-page: 67 year: 2008 ident: hep27678-bib-0011-20241017 article-title: The obesity epidemic and nonalcoholic fatty liver disease in children publication-title: Curr Gastroenterol Rep doi: 10.1007/s11894-008-0011-1 – volume: 10 start-page: 686 year: 2013 ident: hep27678-bib-0001-20241017 article-title: The global NAFLD epidemic publication-title: Nat Rev Gastroenterol Hepatol doi: 10.1038/nrgastro.2013.171 – volume: 7 start-page: 234 year: 2009 ident: hep27678-bib-0007-20241017 article-title: Long‐term follow‐up of patients with nonalcoholic fatty liver publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2008.11.005 – volume: 42 start-page: 641 year: 2005 ident: hep27678-bib-0019-20241017 article-title: Histopathology of pediatric nonalcoholic fatty liver disease publication-title: Hepatology doi: 10.1002/hep.20842 – volume: 105 start-page: 2093 year: 2010 ident: hep27678-bib-0071-20241017 article-title: Association between metabolic syndrome and liver histology among children with nonalcoholic Fatty liver disease publication-title: Am J Gastroenterol doi: 10.1038/ajg.2010.152 – volume: 31 start-page: 1100 year: 2010 ident: hep27678-bib-0051-20241017 article-title: Sodium taurocholate inhibits intestinal adenoma formation in APCMin/+ mice, potentially through activation of the farnesoid X receptor publication-title: Carcinogenesis doi: 10.1093/carcin/bgq050 – volume: 145 start-page: 782 year: 2013 ident: hep27678-bib-0069-20241017 article-title: Simple noninvasive systems predict long‐term outcomes of patients with nonalcoholic fatty liver disease publication-title: Gastroenterology doi: 10.1053/j.gastro.2013.06.057 – volume: 36 start-page: 920 year: 2004 ident: hep27678-bib-0049-20241017 article-title: Liver transplant recipients mortality on the waiting list: long‐term comparison to Child-Pugh classification and MELD publication-title: Transplant Proc doi: 10.1016/j.transproceed.2004.03.095 – volume: 56 start-page: A1480 year: 2012 ident: hep27678-bib-0038-20241017 article-title: Histological predictors of improvement of NASH: results from NASH Clinical Research Network PIVENS trial publication-title: Hepatology – volume: 4 start-page: 129 year: 2010 ident: hep27678-bib-0002-20241017 article-title: Non‐alcoholic fatty liver disease (NAFLD): new challenge for general practitioners and important burden for health authorities? publication-title: Prim Care Diabetes doi: 10.1016/j.pcd.2010.02.004 – volume: 41 start-page: 1313 year: 2005 ident: hep27678-bib-0016-20241017 article-title: Design and validation of a histological scoring system for nonalcoholic fatty liver disease publication-title: Hepatology doi: 10.1002/hep.20701 – volume: 26 start-page: 2183 year: 2010 ident: hep27678-bib-0034-20241017 article-title: Population‐based risk factors and resource utilization for HCC: US perspective publication-title: Curr Med Res Opin doi: 10.1185/03007995.2010.506375 – volume: 51 start-page: 1972 year: 2010 ident: hep27678-bib-0036-20241017 article-title: The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis publication-title: Hepatology doi: 10.1002/hep.23527 – volume: 42 start-page: 793 year: 2005 ident: hep27678-bib-0055-20241017 article-title: Influence of hepatic venous pressure gradient on the prediction of survival of patients with cirrhosis in the MELD era publication-title: Hepatology doi: 10.1002/hep.20871 – volume: 39 start-page: 280 year: 2004 ident: hep27678-bib-0057-20241017 article-title: The hepatic venous pressure gradient: anything worth doing should be done right publication-title: Hepatology doi: 10.1002/hep.20062 – volume: 129 start-page: 113 year: 2005 ident: hep27678-bib-0006-20241017 article-title: The natural history of nonalcoholic fatty liver disease: a population‐based cohort study publication-title: Gastroenterology doi: 10.1053/j.gastro.2005.04.014 – volume: 44 start-page: 217 year: 2006 ident: hep27678-bib-0029-20241017 article-title: Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies publication-title: J Hepatol doi: 10.1016/j.jhep.2005.10.013 – volume: 155 start-page: 469 year: 2009 ident: hep27678-bib-0072-20241017 article-title: Pediatric nonalcoholic fatty liver disease in 2009 publication-title: J Pediatr doi: 10.1016/j.jpeds.2009.06.014 – volume: 10 start-page: 656 year: 2013 ident: hep27678-bib-0043-20241017 article-title: NAFLD, NASH and liver cancer publication-title: Nat Rev Gastroenterol Hepatol doi: 10.1038/nrgastro.2013.183 – volume: 7 start-page: 122 year: 1987 ident: hep27678-bib-0028-20241017 article-title: Compensated cirrhosis: natural history and prognostic factors publication-title: Hepatology doi: 10.1002/hep.1840070124 – volume: 43 start-page: 682 year: 2006 ident: hep27678-bib-0030-20241017 article-title: Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C publication-title: Hepatology doi: 10.1002/hep.21103 – volume: 42 start-page: 132 year: 2005 ident: hep27678-bib-0014-20241017 article-title: The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies publication-title: J Hepatol doi: 10.1016/j.jhep.2004.09.012 – volume: 94 start-page: 2467 year: 1999 ident: hep27678-bib-0017-20241017 article-title: Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions publication-title: Am J Gastroenterol doi: 10.1111/j.1572-0241.1999.01377.x – volume: 52 start-page: 913 year: 2010 ident: hep27678-bib-0010-20241017 article-title: Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease publication-title: Hepatology doi: 10.1002/hep.23784 – volume: 124 start-page: 91 year: 2003 ident: hep27678-bib-0048-20241017 article-title: Model for end‐stage liver disease (MELD) and allocation of donor livers publication-title: Gastroenterology doi: 10.1053/gast.2003.50016 – volume: 32 start-page: 1351 year: 2010 ident: hep27678-bib-0058-20241017 article-title: Comparison of balloon vs. straight catheter for the measurement of portal hypertension publication-title: Aliment Pharmacol Ther doi: 10.1111/j.1365-2036.2010.04484.x – volume: 28 start-page: 1209 year: 2013 ident: hep27678-bib-0050-20241017 article-title: Predictive value of refit MELD, refit MELD‐Na and pre-existing scoring system for 3 month mortality in Korean patients with cirrhosis publication-title: J Gastroenterol Hepatol doi: 10.1111/jgh.12156 – volume: 55 start-page: 434 year: 1980 ident: hep27678-bib-0008-20241017 article-title: Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease publication-title: Mayo Clin Proc doi: 10.1016/S0025-6196(24)00530-5 – volume: 44 start-page: 865 year: 2006 ident: hep27678-bib-0015-20241017 article-title: Long‐term follow‐up of patients with NAFLD and elevated liver enzymes publication-title: Hepatology doi: 10.1002/hep.21327 – volume: 109 start-page: 1757 year: 2014 ident: hep27678-bib-0042-20241017 article-title: Covert hepatic encephalopathy is independently associated with poor survival and increased risk of hospitalization publication-title: Am J Gastroenterol doi: 10.1038/ajg.2014.264 – volume: 53 start-page: 1874 year: 2011 ident: hep27678-bib-0066-20241017 article-title: Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver‐related mortality publication-title: Hepatology doi: 10.1002/hep.24268 – volume: 7 start-page: 567 year: 1983 ident: hep27678-bib-0059-20241017 article-title: Portal venous pressure measurement and its clinical significance publication-title: Lab Res Methods Biol Med – volume: 15 start-page: 2097 year: 2009 ident: hep27678-bib-0061-20241017 article-title: Bile‐acid‐activated farnesoid X receptor regulates hydrogen sulfide production and hepatic microcirculation publication-title: World J Gastroenterol doi: 10.3748/wjg.15.2097 – volume: 19 start-page: 2969 year: 2009 ident: hep27678-bib-0062-20241017 article-title: Substituted isoxazole analogs of farnesoid X receptor (FXR) agonist GW4064 publication-title: Bioorg Med Chem Lett doi: 10.1016/j.bmcl.2009.04.047 – volume: 33 start-page: 464 year: 2001 ident: hep27678-bib-0047-20241017 article-title: A model to predict survival in patients with end‐stage liver disease publication-title: Hepatology doi: 10.1053/jhep.2001.22172 – volume: 58 start-page: A114 year: 2013 ident: hep27678-bib-0064-20241017 article-title: Serum keratin fgragment 18 (CK18) levels significantly predict changes in liver histology in children and adolescents with nonalcoholic fatty liver disease: results from teh TONIC trial publication-title: Hepatology – volume: 142 start-page: 1592 year: 2012 ident: hep27678-bib-0009-20241017 article-title: The diagnosis and management of non‐alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology publication-title: Gastroenterology doi: 10.1053/j.gastro.2012.04.001 – volume: 58 start-page: 495A year: 2013 ident: hep27678-bib-0068-20241017 article-title: Progression to bridging fibrosis in nonalcoholic fatty liver disease over 4 years in the NASH CRN publication-title: Hepatology – volume: 135 start-page: 1961 year: 2008 ident: hep27678-bib-0012-20241017 article-title: Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis publication-title: Gastroenterology doi: 10.1053/j.gastro.2008.08.050 – volume: 96 start-page: 2199 year: 2001 ident: hep27678-bib-0025-20241017 article-title: Health‐related quality of life in chronic liver disease: the impact of type and severity of disease publication-title: Am J Gastroenterol doi: 10.1111/j.1572-0241.2001.03956.x – volume: 43 start-page: 413 year: 2006 ident: hep27678-bib-0005-20241017 article-title: Pediatric nonalcoholic fatty liver disease: a critical appraisal of current data and implications for future research publication-title: J Pediatr Gastroenterol Nutr doi: 10.1097/01.mpg.0000239995.58388.56 – volume: 10 start-page: S69 year: 2004 ident: hep27678-bib-0056-20241017 article-title: When is a patient too well and when is a patient too sick for a liver transplant? publication-title: Liver Transpl doi: 10.1002/lt.20265 – volume: 103 start-page: 2263 year: 2008 ident: hep27678-bib-0074-20241017 article-title: Suspected nonalcoholic fatty liver disease and mortality risk in a population‐based cohort study publication-title: Am J Gastroenterol doi: 10.1111/j.1572-0241.2008.02034.x – volume: 116 start-page: 1413 year: 1999 ident: hep27678-bib-0035-20241017 article-title: Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity publication-title: Gastroenterology doi: 10.1016/S0016-5085(99)70506-8 – volume: 54 start-page: 1208 year: 2011 ident: hep27678-bib-0033-20241017 article-title: The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study publication-title: Hepatology doi: 10.1002/hep.24491 – volume: 18 start-page: 685 year: 2011 ident: hep27678-bib-0044-20241017 article-title: Use of transient elastography (FibroScan(R)) for the noninvasive assessment of portal hypertension in HIV/HCV‐coinfected patients publication-title: J Viral Hepat doi: 10.1111/j.1365-2893.2010.01371.x – volume: 48 start-page: 597 year: 2009 ident: hep27678-bib-0073-20241017 article-title: Trends in nonalcoholic fatty liver disease‐related hospitalizations in US children, adolescents, and young adults publication-title: J Pediatr Gastroenterol Nutr doi: 10.1097/MPG.0b013e318192d224 – volume: 58 start-page: 3017 year: 2013 ident: hep27678-bib-0018-20241017 article-title: Predictors of all‐cause mortality and liver‐related mortality in patients with non‐alcoholic fatty liver disease (NAFLD) publication-title: Dig Dis Sci doi: 10.1007/s10620-013-2743-5 – volume: 57 start-page: 1357 year: 2013 ident: hep27678-bib-0070-20241017 article-title: Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States publication-title: Hepatology doi: 10.1002/hep.26156 – volume: 11 start-page: 74 year: 1990 ident: hep27678-bib-0037-20241017 article-title: The natural history of nonalcoholic steatohepatitis: a follow‐up study of forty‐two patients for up to 21 years publication-title: Hepatology doi: 10.1002/hep.1840110114 – volume: 32 start-page: 945 year: 2012 ident: hep27678-bib-0075-20241017 article-title: The Framingham risk score and heart disease in nonalcoholic fatty liver disease publication-title: Liver Int doi: 10.1111/j.1478-3231.2011.02753.x – volume: 49 start-page: 1904 year: 2009 ident: hep27678-bib-0023-20241017 article-title: Quality of life in adults with nonalcoholic fatty liver disease: baseline data from the nonalcoholic steatohepatitis clinical research network publication-title: Hepatology doi: 10.1002/hep.22868 – volume: 51 start-page: 380 year: 2009 ident: hep27678-bib-0053-20241017 article-title: Farnesoid X receptor agonist WAY‐362450 attenuates liver inflammation and fibrosis in murine model of non‐alcoholic steatohepatitis publication-title: J Hepatol doi: 10.1016/j.jhep.2009.03.025 – volume: 10 start-page: 330 year: 2013 ident: hep27678-bib-0020-20241017 article-title: Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis publication-title: Nat Rev Gastroenterol Hepatol doi: 10.1038/nrgastro.2013.41 – volume: 37 start-page: 1286 year: 2003 ident: hep27678-bib-0013-20241017 article-title: Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values publication-title: Hepatology doi: 10.1053/jhep.2003.50229 – volume: 68 start-page: 563 year: 2006 ident: hep27678-bib-0026-20241017 article-title: Depression, anxiety, and nonalcoholic steatohepatitis publication-title: Psychosom Med doi: 10.1097/01.psy.0000221276.17823.df – volume: 97 start-page: 2058 year: 2002 ident: hep27678-bib-0021-20241017 article-title: Subacute liver failure in obese women publication-title: Am J Gastroenterol doi: 10.1111/j.1572-0241.2002.05922.x – volume: 398 start-page: 185 year: 2010 ident: hep27678-bib-0052-20241017 article-title: Identification of farnesoid X receptor modulators by a fluorescence polarization‐based interaction assay publication-title: Anal Biochem doi: 10.1016/j.ab.2009.11.008 – volume: 28 start-page: 110 year: 2008 ident: hep27678-bib-0046-20241017 article-title: Assessment of prognosis of cirrhosis publication-title: Semin Liver Dis doi: 10.1055/s-2008-1040325 – volume: 133 start-page: 481 year: 2007 ident: hep27678-bib-0031-20241017 article-title: Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis publication-title: Gastroenterology doi: 10.1053/j.gastro.2007.05.024 – volume: 7 start-page: 195 year: 2010 ident: hep27678-bib-0003-20241017 article-title: Pathology of nonalcoholic fatty liver disease publication-title: Nat Rev Gastroenterol Hepatol doi: 10.1038/nrgastro.2010.21 – volume: 40 start-page: 1387 year: 2004 ident: hep27678-bib-0004-20241017 article-title: Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity publication-title: Hepatology doi: 10.1002/hep.20466 – volume: 15 start-page: 301 year: 2013 ident: hep27678-bib-0041-20241017 article-title: Quality of life in cirrhosis publication-title: Curr Gastroenterol Rep doi: 10.1007/s11894-012-0301-5 – volume: 17 start-page: 139 year: 2010 ident: hep27678-bib-0054-20241017 article-title: Targetting farnesoid‐X‐receptor: from medicinal chemistry to disease treatment publication-title: Curr Med Chem doi: 10.2174/092986710790112666 – volume: 32 start-page: 1407 year: 2012 ident: hep27678-bib-0060-20241017 article-title: Prognostic indicators of survival in patients with compensated and decompensated cirrhosis publication-title: Liver Int doi: 10.1111/j.1478-3231.2012.02830.x – volume: 128 start-page: 1898 year: 2005 ident: hep27678-bib-0067-20241017 article-title: Sampling variability of liver biopsy in nonalcoholic fatty liver disease publication-title: Gastroenterology doi: 10.1053/j.gastro.2005.03.084 – volume: 26 start-page: 815 year: 2007 ident: hep27678-bib-0024-20241017 article-title: Health‐related quality of life in patients with non‐alcoholic fatty liver disease publication-title: Aliment Pharmacol Ther doi: 10.1111/j.1365-2036.2007.03426.x – volume: 120 start-page: 170 year: 2001 ident: hep27678-bib-0040-20241017 article-title: Factors associated with poor health‐related quality of life of patients with cirrhosis publication-title: Gastroenterology doi: 10.1053/gast.2001.21193 – volume: 105 start-page: 1567 year: 2010 ident: hep27678-bib-0076-20241017 article-title: Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community‐based cohort study publication-title: Am J Gastroenterol doi: 10.1038/ajg.2010.18 – volume: 50 start-page: 923 year: 2009 ident: hep27678-bib-0063-20241017 article-title: Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis publication-title: J Hepatol doi: 10.1016/j.jhep.2009.01.014 – volume: 362 start-page: 1675 year: 2010 ident: hep27678-bib-0039-20241017 article-title: Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis publication-title: N Engl J Med doi: 10.1056/NEJMoa0907929 – volume: 134 start-page: 85 year: 2008 ident: hep27678-bib-0032-20241017 article-title: Impact of fatty liver disease on health care utilization and costs in a general population: a 5‐year observation publication-title: Gastroenterology doi: 10.1053/j.gastro.2007.10.024 – volume: 144 start-page: S951 year: 2013 ident: hep27678-bib-0065-20241017 article-title: Changes in serum cytokeratin 18 levels significantly predict changes in liver histology in adults with nonalcoholic steatohepatitis: results from the PIVENS Trial publication-title: Gastroenterology doi: 10.1016/S0016-5085(13)63534-9 – volume: 31 start-page: 396 year: 2010 ident: hep27678-bib-0022-20241017 article-title: Symptoms and quality of life in obese children and adolescents with non‐alcoholic fatty liver disease publication-title: Aliment Pharmacol Ther doi: 10.1111/j.1365-2036.2009.04181.x – reference: 20460905 - Dig Dis. 2010;28(1):155-61 – reference: 15940625 - Gastroenterology. 2005 Jun;128(7):1898-906 – reference: 18417045 - Curr Gastroenterol Rep. 2008 Feb;10(1):67-72 – reference: 23775317 - Dig Dis Sci. 2013 Oct;58(10):3017-23 – reference: 2680867 - Hepatology. 1989 Nov;10(5):846-50 – reference: 24042449 - Nat Rev Gastroenterol Hepatol. 2013 Nov;10(11):686-90 – reference: 21155882 - J Gastroenterol Hepatol. 2011 Mar;26(3):510-6 – reference: 19863497 - Aliment Pharmacol Ther. 2010 Feb 1;31(3):396-406 – reference: 20666689 - Curr Med Res Opin. 2010 Sep;26(9):2183-91 – reference: 10348825 - Gastroenterology. 1999 Jun;116(6):1413-9 – reference: 18293281 - Semin Liver Dis. 2008 Feb;28(1):110-22 – reference: 3804191 - Hepatology. 1987 Jan-Feb;7(1):122-8 – reference: 15382215 - Liver Transpl. 2004 Oct;10(10 Suppl 2):S69-73 – reference: 10733541 - Hepatology. 2000 Apr;31(4):864-71 – reference: 20372110 - Am J Gastroenterol. 2010 Sep;105(9):2093-102 – reference: 21726509 - Gastroenterology. 2011 Oct;141(4):1249-53 – reference: 24247899 - Transplantation. 2013 Nov 27;96(10):860-2 – reference: 22299674 - Liver Int. 2012 Jul;32(6):945-50 – reference: 17033514 - J Pediatr Gastroenterol Nutr. 2006 Oct;43(4):413-27 – reference: 20195271 - Nat Rev Gastroenterol Hepatol. 2010 Apr;7(4):195-203 – reference: 2295475 - Hepatology. 1990 Jan;11(1):74-80 – reference: 20209604 - Hepatology. 2010 Jun;51(6):1972-8 – reference: 23860502 - Gastroenterology. 2013 Oct;145(4):782-9.e4 – reference: 17006923 - Hepatology. 2006 Oct;44(4):865-73 – reference: 22656328 - Gastroenterology. 2012 Jun;142(7):1592-609 – reference: 21556040 - Am J Gastroenterol. 2011 Sep;106(9):1646-53 – reference: 10220741 - Liver. 1999 Apr;19(2):115-21 – reference: 11172350 - Hepatology. 2001 Feb;33(2):464-70 – reference: 20299294 - Prim Care Diabetes. 2010 Oct;4(3):129-37 – reference: 21431854 - Curr Diab Rep. 2011 Jun;11(3):167-72 – reference: 18684196 - Am J Gastroenterol. 2008 Sep;103(9):2263-71 – reference: 16502396 - Hepatology. 2006 Apr;43(4):682-9 – reference: 23175136 - Hepatology. 2013 Apr;57(4):1357-65 – reference: 18005961 - Gastroenterology. 2008 Jan;134(1):85-94 – reference: 20101752 - Hepatology. 2010 Feb;51(2):585-94 – reference: 19773396 - J Clin Endocrinol Metab. 2009 Oct;94(10):3872-81 – reference: 15565570 - Hepatology. 2004 Dec;40(6):1387-95 – reference: 14767976 - Hepatology. 2004 Feb;39(2):280-2 – reference: 12190177 - Am J Gastroenterol. 2002 Aug;97(8):2058-62 – reference: 16175621 - Hepatology. 2005 Oct;42(4):793-801 – reference: 24375711 - Hepatology. 2014 Jun;59(6):2188-95 – reference: 15643990 - Am J Transplant. 2005 Feb;5(2):307-13 – reference: 16298014 - J Hepatol. 2006 Jan;44(1):217-31 – reference: 20145609 - Am J Gastroenterol. 2010 Jul;105(7):1567-73 – reference: 15915461 - Hepatology. 2005 Jun;41(6):1313-21 – reference: 6353113 - Lab Res Methods Biol Med. 1983;7:567-85 – reference: 2737595 - Hepatology. 1989 Jul;10(1):1-7 – reference: 19772998 - J Pediatr. 2009 Oct;155(4):469-74 – reference: 10464138 - Gastroenterology. 1999 Sep;117(3):626-31 – reference: 7382552 - Mayo Clin Proc. 1980 Jul;55(7):434-8 – reference: 19049831 - Clin Gastroenterol Hepatol. 2009 Feb;7(2):234-8 – reference: 10484010 - Am J Gastroenterol. 1999 Sep;94(9):2467-74 – reference: 2227807 - Hepatology. 1990 Nov;12(5):1106-10 – reference: 22989165 - J Gastroenterol Hepatol. 2013 Jan;28(1):142-7 – reference: 22679906 - Liver Int. 2012 Oct;32(9):1407-14 – reference: 20648476 - Hepatology. 2010 Sep;52(3):913-24 – reference: 16116629 - Hepatology. 2005 Sep;42(3):641-9 – reference: 15629518 - J Hepatol. 2005 Jan;42(1):132-8 – reference: 12648985 - Lancet. 2003 Mar 15;361(9361):952-4 – reference: 17767465 - Aliment Pharmacol Ther. 2007 Sep 15;26(6):815-20 – reference: 20336705 - Hepatology. 2010 Jun;51(6):1979-87 – reference: 23507799 - Nat Rev Gastroenterol Hepatol. 2013 Jun;10(6):330-44 – reference: 24607623 - J Hepatol. 2014 Jul;61(1):22-7 – reference: 12512033 - Gastroenterology. 2003 Jan;124(1):91-6 – reference: 20844956 - Dig Dis Sci. 2011 Apr;56(4):977-87 – reference: 21688282 - Hepatology. 2011 Oct;54(4):1208-16 – reference: 21360720 - Hepatology. 2011 Jun;53(6):1874-82 – reference: 19412009 - J Pediatr Gastroenterol Nutr. 2009 May;48(5):597-603 – reference: 16868265 - Psychosom Med. 2006 Jul-Aug;68(4):563-9 – reference: 20427778 - N Engl J Med. 2010 May 6;362(18):1675-85 – reference: 17681169 - Gastroenterology. 2007 Aug;133(2):481-8 – reference: 23250701 - Curr Gastroenterol Rep. 2013 Jan;15(1):301 – reference: 21050237 - Aliment Pharmacol Ther. 2010 Dec;32(11-12):1351-6 – reference: 11467653 - Am J Gastroenterol. 2001 Jul;96(7):2199-205 – reference: 19434741 - Hepatology. 2009 Jun;49(6):1904-12 – reference: 12774006 - Hepatology. 2003 Jun;37(6):1286-92 – reference: 19293782 - Am J Gastroenterol. 2009 Apr;104(4):861-7 – reference: 19303163 - J Hepatol. 2009 May;50(5):923-8 – reference: 19013463 - Gastroenterology. 2008 Dec;135(6):1961-1971.e2 – reference: 11208726 - Gastroenterology. 2001 Jan;120(1):170-8 – reference: 16012941 - Gastroenterology. 2005 Jul;129(1):113-21 – reference: 23954643 - Clin Gastroenterol Hepatol. 2013 Dec;11(12):1573-84.e1-2; quiz e88-9 |
| SSID | ssj0009428 |
| Score | 2.5889385 |
| Snippet | Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease (CLD) in North America. It is a growing contributor to the burden of... |
| SourceID | proquest pubmed crossref wiley |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1392 |
| SubjectTerms | Biomarkers - analysis Clinical Trials as Topic Congresses as Topic Drugs, Investigational Hepatology Humans Liver cirrhosis Liver diseases Mortality Non-alcoholic Fatty Liver Disease - diagnosis Non-alcoholic Fatty Liver Disease - drug therapy |
| Title | Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an American Association for the Study of Liver Diseases–U.S. Food and Drug Administration Joint Workshop |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fhep.27678 https://www.ncbi.nlm.nih.gov/pubmed/25557690 https://www.proquest.com/docview/1666305583 https://www.proquest.com/docview/1667351256 https://www.proquest.com/docview/1673384962 |
| Volume | 61 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaqHhAX3o-FggbEgUvSNHFiB06o29WqoggBK_WAFMWO00ZAstpsDnDiP_APufMfmLGTLMtLiFskO9bYGdvfZGa-YexRqPK4MFx6RGbu8bQMvFQY4SkVKiVNLF362MmLZL7gx6fx6Q57OuTCOH6I8Ycb7Qx7XtMGz1W7vyENPTdLPxR41uL5exAlxJs_fbWhjkq5rauKVldA3uV0YBUKwv3xze276BeAuY1X7YUzu8zeDqK6OJN3frdWvv70E4vjf87lCrvUA1F45jTnKtsx9TV24aR3tV9n3w6HMist5HUBzZKQeldbBlaoaihW3ZltoQx-CvJZQbGJQAIEw1ATzLcleCsNpE7rBmUgBa3aJzCrbEaNG54M8w_4oivx1AKlvWADDB4l-EGP7NgIXIGCID9CU8Jzii6BqXM2tV8_f1n4r32YNU1hB5-SqNs0wXDcVCgl-Qra82Z5gy1mR28O515fG8LT5OjzElwuI0NTJklONlzEtcqJOCgWhdQhwlY07Q-4KAOuBLlKhdFoCyM4ETrneOrcZLu4COY2A2NIK6VWCAZ5YnRqNCpoiRe1jFSk5YQ9HrQk0z1xOtXveJ85yucww6XL7OebsIdj16VjC_ldp71B1bL-wGgz8t4S-ZqMJuzB2Ixbnfw3eW2azvYREQK0OPlbHxFFEicYTtgtp8ajJGg9onWZBjghq4x_FjGbH720D3f-vetddhHBZOyimvbY7nrVmXsI2Nbqvt2Z3wG4ykFd |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELaWRQIuvB-FBQbEgUuyIXHiBHFB263K0q4QbKW9rKLYcdgISKqmOcCJ_8A_5M5_YMZuUspLiFskO9bYGdvfZGa-YeyRL7Mw1zx2iMzc4UnhOYnQwpHSlzLWYWzTx6aH0XjGD47D4y32rMuFsfwQ_Q832hnmvKYNTj-kd9esoad67voCD9sz7CxHoEGm1_D1mjwq4aayKtpdHvmXk45XyPN3-1c3b6NfIOYmYjVXzugSO-mEtZEm79x2KV316Scex_-dzWV2cYVF4blVnitsS1dX2bnpytt-jX3b6yqtNJBVOdRzAuttZUhYoawgX7RvTQsl8VOczwLydRASIB6GipC-qcJbKiCNWtYoA-lo2TyFUWmSauzwZJt_wBdtlacGKPMFG6BzKsEPqmTGRuwKFAf5EeoCJhRgAkPrb2q-fv4yc9-4MKrr3Aw-JFE3mYLhoC5RSnIXNKf1_DqbjfaP9sbOqjyEo8jX50S4XDr2dRFFGZlxAVcyI-6gUOSx8hG5onX_hIvC41KQt1RoheYw4hOhMo4Hzw22jYugbzHQmhQzVhLxII-0SrRCHS3wro4DGah4wB53apKqFXc6lfB4n1rWZz_FpUvN5xuwh33XuSUM-V2nnU7X0tWZ0aTkwCX-tTgYsAd9M-52cuFkla5b00cEiNHC6G99RBDEOEF_wG5aPe4lQQMSDczEwwkZbfyziOl4_5V5uP3vXe-z8-Oj6SSdvDh8eYddQGwZ2iCnHba9XLT6LuK3pbxntul3ovhFfA |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbtQwELZKkSou_FMWChjEgUvSkDixAyfUbbSUtqqAlXpAimLHoRGQRJvNAU68A2_InXdgxk6yLH9C3CLZscbO2P4mM_MNIQ99mYW5ZsJBMnOHxYXnxFxzR0pfSqFDYdPHjo6j2ZwdnIanG-TpkAtj-SHGH264M8x5jRu8yYvdFWnomW5cn8NZe46cZxEgCUREL1fcUTEzhVXB7PLQvRwPtEKevzu-un4Z_YIw1wGruXGSS-TNIKsNNHnndkvpqk8_0Tj-52Quk4s9EqXPrOpcIRu6ukq2jnpf-zXybW-os9LSrMpp3SBU7ypDwUrLiuaL7q1pwRR-jPJZ0HwVgkQBDdMKcb6pwVsqivq0rEEG1NCyfUKT0qTU2OHRMv8AL9oaTy3FvBdooINLif6gSGZsQK4UoyA_0rqghxheQqfW29R-_fxl7r5yaVLXuRl8iqKu8wTTg7oEKdFZ0J7VzXUyT_Zf782cvjiEo9DT50SwXFr4uoiiDI24gCmZIXNQyHOhfMCtYNs_ZrzwmOToK-VagTEM6ISrjMGxc4NswiLom4RqjWoplAQ0yCKtYq1AQwu4qUUgAyUm5NGgJanqmdOxgMf71HI--yksXWo-34Q8GLs2li7kd512BlVL-xOjTdF9i-xrIpiQ-2Mz7HV04GSVrjvThweA0MLob314EAiYoD8h21aNR0nAfATzMvZgQkYZ_yxiOts_MQ-3_r3rPbJ1Mk3Sw-fHL26TCwAsQxvhtEM2l4tO3wHwtpR3zSb9Dqt1RCs |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Challenges+and+opportunities+in+drug+and+biomarker+development+for+nonalcoholic+steatohepatitis%3A+findings+and+recommendations+from+an+American+Association+for+the+Study+of+Liver+Diseases-U.S.+Food+and+Drug+Administration+Joint+Workshop&rft.jtitle=Hepatology+%28Baltimore%2C+Md.%29&rft.au=Sanyal%2C+Arun+J&rft.au=Friedman%2C+Scott+L&rft.au=McCullough%2C+Arthur+J&rft.au=Dimick-Santos%2C+Lara&rft.date=2015-04-01&rft.issn=1527-3350&rft.eissn=1527-3350&rft.volume=61&rft.issue=4&rft.spage=1392&rft_id=info:doi/10.1002%2Fhep.27678&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0270-9139&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0270-9139&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0270-9139&client=summon |